The stock of Lannett Company, Inc. (NYSE:LCI) is a huge mover today! About 1.19 million shares traded hands. Lannett Company, Inc. (NYSE:LCI) has declined 2.81% since April 6, 2016 and is downtrending. It has underperformed by 4.77% the S&P500.
The move comes after 8 months negative chart setup for the $701.55 million company. It was reported on Nov, 8 by Barchart.com. We have $17.25 PT which if reached, will make NYSE:LCI worth $42.09 million less.
Lannett Company, Inc. (NYSE:LCI) Ratings Coverage
Out of 8 analysts covering Lannett (NYSE:LCI), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. Lannett has been the topic of 20 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The rating was upgraded by Craig Hallum to “Buy” on Thursday, February 4. The stock of Lannett Company, Inc. (NYSE:LCI) earned “Buy” rating by Roth Capital on Wednesday, August 26. Roth Capital maintained Lannett Company, Inc. (NYSE:LCI) rating on Friday, March 11. Roth Capital has “Buy” rating and $3 price target. The stock of Lannett Company, Inc. (NYSE:LCI) earned “Buy” rating by Roth Capital on Thursday, September 3. The stock of Lannett Company, Inc. (NYSE:LCI) has “Hold” rating given on Thursday, November 5 by Craig Hallum. The rating was maintained by TH Capital on Thursday, September 3 with “Buy”. The stock has “Strong-Buy” rating given by Zacks on Monday, September 7. The stock has “Buy” rating given by Roth Capital on Thursday, March 24. As per Thursday, March 24, the company rating was downgraded by Canaccord Genuity. Deutsche Bank initiated Lannett Company, Inc. (NYSE:LCI) on Wednesday, June 29 with “Hold” rating.
According to Zacks Investment Research, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies.”
Insitutional Activity: The institutional sentiment increased to 0.88 in 2016 Q2. Its up 0.07, from 0.81 in 2016Q1. The ratio increased, as 38 funds sold all Lannett Company, Inc. shares owned while 51 reduced positions. 27 funds bought stakes while 51 increased positions. They now own 27.61 million shares or 4.85% less from 29.01 million shares in 2016Q1.
The Kansas-based Creative Planning has invested 0% in Lannett Company, Inc. (NYSE:LCI). Gp One Trading Lp has invested 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI). Gsa Capital Prtn Ltd Liability Partnership has 0.09% invested in the company for 64,890 shares. Piedmont Investment Advisors Limited Liability reported 70 shares or 0% of all its holdings. Teachers Advisors Inc last reported 44,360 shares in the company. California Pub Employees Retirement System accumulated 0% or 89,100 shares. Kennedy Cap Incorporated reported 106,822 shares or 0.05% of all its holdings. Victory Capital Mngmt Incorporated, a Ohio-based fund reported 1,803 shares. Moreover, Eqis Inc has 0.02% invested in Lannett Company, Inc. (NYSE:LCI) for 11,822 shares. Mesirow Invest Management holds 11,315 shares or 0.02% of its portfolio. Sei Communication, a Pennsylvania-based fund reported 281 shares. Moreover, Herndon Capital Mgmt Lc has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 313 shares. Vanguard has 0% invested in the company for 2.06 million shares. Northern Tru accumulated 0% or 362,656 shares. Pinnacle Assocs has 0.05% invested in the company for 103,110 shares.
Insider Transactions: Since August 31, 2016, the stock had 0 buys, and 3 sales for $416,823 net activity. 4,334 shares were sold by Landis G. Michael, worth $139,988 on Thursday, September 15. $50,119 worth of Lannett Company, Inc. (NYSE:LCI) was sold by Maher James M. on Thursday, September 1.
More notable recent Lannett Company, Inc. (NYSE:LCI) news were published by: Businesswire.com which released: “LANNETT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn …” on November 08, 2016, also Fool.com with their article: “Why Lannett Company, Inc. Shares Got Pummeled Today” published on October 17, 2016, Businesswire.com published: “IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Lannett …” on November 08, 2016. More interesting news about Lannett Company, Inc. (NYSE:LCI) were released by: Businesswire.com and their article: “Glancy Prongay & Murray LLP Commences Investigation on Behalf of Lannett …” published on November 03, 2016 as well as Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” with publication date: November 04, 2016.
LCI Company Profile
Lannett Company, Inc., incorporated on December 3, 1991, develops, makes, markets and distributes generic versions of brand pharmaceutical products. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Firm has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.